BLRX Company Profile and Key Details

Q: Who are the executives of BLRX?

Dr. Abi Vainstein-Haras M.D.Chief Medical OfficerMr. Adam Janoff Esq.Gen. Counsel & Head of ComplianceMs. Mali Zeevi CPA, CPAChief Financial OfficerAdvocate Norman KotlerInternal Enforcement Officer, Gen. Counsel and Corporation Sec.Ms. Holly W. May M.B.A.Pres of BioLineRx USAMr. Raziel FriedTreasurer & Budgetary Control DirectorDr. Ella SoraniChief Devel. OfficerMr. Philip A. Serlin CPA, M.B.A., CPA, MBAChief Executive OfficerMr. John LaceyHead of Corporation Communications & Investor RelationsMs. Jael Birenberg M.Sc.Senior Director & Head of RA, QA and PhVMs. Tsipi Keren-Lehrer B.Sc., L.L.B.Head of BD & Strategic AdvisorMs. Liron Shemesh-Darvish M.B.A., Ph.D.Senior Director & Head of Preclinical Devel.

NASDAQ : BLRX

BioLineRx

$2.88

-0.16-5.26%

At Close 4:00 PM

71.42

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

BioLineRx Ltd. (BLRX) stock surged +4.17%, trading at $3.00 on NASDAQ, up from the previous close of $2.88. The stock opened at $2.95, fluctuating between $2.83 and $3.00 in the recent session.

Stock Snapshot

2.88

Prev. Close

13.05M

Market Cap

2.83

Day Low

-0.5

P/E Ratio

-6

EPS (TTM)

-0.32

Cash Flow per Share

2.95

Open

4.35M

Number of Shares

Day High

99.44%

Free Float in %

0.18

Book Value

46.36K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 22, 2025	3.08	3.09	2.88	2.88	21.81K
Dec 19, 2025	2.96	3.10	2.92	3.04	20.2K
Dec 17, 2025	3.02	3.10	2.87	2.98	21.08K
Dec 16, 2025	3.13	3.17	3.01	3.01	23.18K
Dec 15, 2025	3.22	3.36	3.17	3.18	36.11K
Dec 12, 2025	3.19	3.31	3.14	3.31	10.95K
Dec 11, 2025	3.26	3.29	3.16	3.24	14.94K
Dec 10, 2025	3.30	3.33	3.16	3.31	50.8K
Dec 09, 2025	3.32	3.36	3.24	3.25	30.92K
Dec 08, 2025	3.19	3.43	3.16	3.32	43.26K
Dec 05, 2025	3.37	3.38	3.25	3.38	6.4K
Dec 04, 2025	3.30	3.39	3.20	3.26	14.4K
Dec 03, 2025	3.38	3.39	3.16	3.22	14.69K
Dec 02, 2025	3.38	3.39	3.14	3.20	15.84K
Dec 01, 2025	3.40	3.50	3.12	3.34	38.77K
Nov 28, 2025	3.40	3.56	3.40	3.47	9.7K
Nov 26, 2025	3.54	3.58	3.36	3.45	19.69K
Nov 25, 2025	3.50	3.86	3.38	3.55	83.04K
Nov 24, 2025	3.43	3.50	3.30	3.50	52.43K
Nov 21, 2025	3.20	3.47	3.20	3.25	19.17K

Contact Details

Hevel Modi'in, 7177871

Israel

https://www.biolinerx.com 972 864 29100

About Company

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Stock Peers

ARGX

-2.95-0.35%

argenx SE$852.04 REGN

11.4+1.48%

Regeneron Pharmaceuticals, Inc.$779.36 MDGL

11.81+2.00%

Madrigal Pharmaceuticals, Inc.$602.83 UTHR

-3.34-0.65%

United Therapeutics Corporation$513.79 VRTX

4.11+0.90%

Vertex Pharmaceuticals Incorporated$460.31 ALNY

7.5+1.87%

Alnylam Pharmaceuticals, Inc.$407.73 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

7.48+2.74%

Praxis Precision Medicines, Inc.$280.40 KRYS

8.81+3.66%

Krystal Biotech, Inc.$249.61 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

BioLineRx Ltd. (NASDAQ:BLRX) closed at $3.00 USD, gaining $0.12 (4.17%) from the previous close of $2.88. The stock is currently mid-range between its 52-week high and low $2.30 and $14.80. With a market capitalization of about $13.05 million, BioLineRx Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.59). Key stats such as the average daily volume over the past year has been around 34.47 thousand shares, in line with its 52-week average. Headquartered in Hevel Modi'in, None, BioLineRx Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Philip A. Serlin, the company employs approximately 28 people and listed since July 27, 2011. BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.

Technical Performance

BLRX has shown weak momentum, losing -12.99% over the past week and -25.58% over the past quarter, though year-to-date performance is down -66.36%. Short-term trend indicators are bullishly aligned (SMA20 -11.15%, SMA50 -15.68%, SMA200 -22.29%). The stock’s 14-day RSI is 35.33 (weak momentum), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -80.4% below its high and over 25.21% above its low. Average 10-day trading volume of 24.48 thousand shares is below the 3-month average of 34.08 thousand, indicating normal recent market interest.

Valuation Metrics

BioLineRx Ltd. trades at a P/E ratio of -1.47, slightly below the S&P 500 average, with a price-to-sales ratio of 0.74 and a price-to-book ratio of 0.57 suggesting the stock is closer to book value. The P/FCF stands at -0.6, also above market averages.

Dividend & Fair Value

BioLineRx Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.76. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

BioLineRx Ltd. generated EPS of -$1.37 over the past year. Five-year average earnings growth is 46.37%. Wall Street analysts project EPS growth of 57.36% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $26.00. The high target offers 802.78% upside. The low target suggests 802.78% downside. The mean target is $26.00. This offers 802.78% upside. BioLineRx Ltd. earnings surprise history is a mixed track record. The quarter that ended November 24, 2025, missed forecasts by -46.34%. The prior quarter beat by 172.99%. Over the last six quarters, Apple has recorded several small beats. These include 40.0% in November 25, 2024.

Shareholding & Insider Activity

BioLineRx Ltd. has 4.26 million shares outstanding. The public float is 2.45 billion shares, elevated short interest at 4.26% of float. This equals 181.21 thousand shares. The short ratio is 4.82 days. Institutional investors hold 1.62% of the float. Insiders own 4.08%.

Financial & Profitability Overview

Over the trailing twelve months, BioLineRx generated $4.80M in revenue, or $0.07 per share. Gross margin was 3.62%, operating margin -895.65%, and net profit margin -1262.79%. Returns are negative, with ROA at -94.82% and ROE at -458.40%.
On valuation metrics, BioLineRx trades at a P/E of -1.47, P/S of 0.74 and P/B of 0.57. The current ratio is 2.06 and quick ratio is 1.87. Operationally, the company’s inventory turnover is 1.89 and cash conversion cycle is -35.83 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.63, supported by a cash flow-to-debt ratio of -1.68.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, BioLineRx posted revenue of $4.80M, down slightly from $0.00 in the prior quarter. Gross profit was $174.00K (margin 3.62%). Operating income was - $42.99M (margin -895.6%). Net income was- $60.61M (EPS - $0.94).
The company ended the quarter with $42.99M in cash and short-term investments, a total debt of $11.59M, and net debt of $7.34M. Total assets were $63.93M, with equity of $13.22M. Financials further reflected weakness, with operating cash flow of - $22.61M, free cash flow of - $22.91M, and capital expenditures of - $297.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that BioLineRx Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.08%, with price expected at $2.82 by January 05, 2026, within a range of $2.70 to $2.94 3-Month Outlook: Projected fall of -44.1%, reaching $1.61 by March 20, 2026, with a range of $1.22 to $2.11. 1-Year Outlook: Projected loss of -53.47%, with price at $1.34 by December 22, 2026, within a range of $0.00 to $0.00.

Key Takeaways

BioLineRx Ltd. (NASDAQ:BLRX) shares are down -66.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BioLineRx Ltd. trading at a premium to the broader market with a P/E of -1.47. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.14, suggesting 321.53% upside. Our AI forecast model points to short-term weakness (-2.08% over two weeks), a medium-term fall (-44.1% over three months), and a longer-term loss (-53.47% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current BioLineRx Ltd. (BLRX) stock price?

BioLineRx Ltd. (NASDAQ: BLRX) stock price is $3.00 in the last trading session. During the trading session, BLRX stock reached the peak price of $3.00 while $2.83 was the lowest point it dropped to. The percentage change in BLRX stock occurred in the recent session was 4.17% while the dollar amount for the price change in BLRX stock was $0.12.

BLRX's industry and sector of operation?

The NASDAQ listed BLRX is part of Biotechnology industry that operates in the broader Healthcare sector. BioLineRx Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BLRX?

Dr. Abi Vainstein-Haras M.D.
Chief Medical Officer
Mr. Adam Janoff Esq.
Gen. Counsel & Head of Compliance
Ms. Mali Zeevi CPA, CPA
Chief Financial Officer
Advocate Norman Kotler
Internal Enforcement Officer, Gen. Counsel and Corporation Sec.
Ms. Holly W. May M.B.A.
Pres of BioLineRx USA
Mr. Raziel Fried
Treasurer & Budgetary Control Director
Dr. Ella Sorani
Chief Devel. Officer
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Chief Executive Officer
Mr. John Lacey
Head of Corporation Communications & Investor Relations
Ms. Jael Birenberg M.Sc.
Senior Director & Head of RA, QA and PhV
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B.
Head of BD & Strategic Advisor
Ms. Liron Shemesh-Darvish M.B.A., Ph.D.
Senior Director & Head of Preclinical Devel.

How BLRX did perform over past 52-week?

BLRX's closing price is 25.22% higher than its 52-week low of $2.30 where as its distance from 52-week high of $14.80 is -80.54%.

How many employees does BLRX have?

Number of BLRX employees currently stands at 28.

Link for BLRX official website?

Official Website of BLRX is: https://www.biolinerx.com

How do I contact BLRX?

BLRX could be contacted at phone 972 864 29100 and can also be accessed through its website. BLRX operates from Modi’in Technology Park, Hevel Modi'in, 7177871, Israel.

How many shares of BLRX are traded daily?

BLRX stock volume for the day was 46.36K shares. The average number of BLRX shares traded daily for last 3 months was 34.47K.

What is the market cap of BLRX currently?

The market value of BLRX currently stands at $13.05M with its latest stock price at $3.00 and 4.35M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	28
Beta	0.59
Sales or Revenue	$4.80M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

BLRX Company Profile and Key Details

BioLineRx

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Technical Performance

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics